

A Study of Relationship Between Hypothyroidism with Central Obesity

Received: 23 August 2022, **Revised:** 19 September 2022, **Accepted:** 21 October 2022

Dr. Ashok Kumar

“Professor, Department of General Medicine, Santosh Medical College & Hospital, Santosh Deemed to be University, Ghaziabad”.

Dr. Shivani Bansal

“Professor, Department of General Medicine, Santosh Medical College & Hospital, Santosh Deemed to be University, Ghaziabad”.

Dr. Shivani Bansal – Corresponding Author

Keywords

Subclinical hypothyroidism (SHG), Metabolic syndrome, serum thyrotropin, dyslipidemia,

Abstract

Background: The precise estimation of the prevalence of important cardiovascular risk factors is of great interest. In order to evaluate the health and nutritional status of “adults and children in the United States”, a series of studies known as the “National Health and Nutrition Examination Survey (NHANES)” was created.

Aim and Objective: To study the co-relation of hypothyroidism with central obesity.

Methodology: The present study was conducted in the “OPD of General Medicine, Santosh medical college and hospital, Ghaziabad, Uttar Pradesh”. In their regular clinical practise, these data would have prognostic significance and consequences for clinicians and to establish strategies for improved treatment of their patients.

Result: On the basis of the IDF criteria for central obesity for the diagnosis, a total of 100 individuals with old and newly diagnosed metabolic syndrome were evaluated. More than half of patients were “females (56%)” and the “prevalence of hypothyroidism” was “higher among female patients (25%) than males (15.9%)”.

Conclusion: The main conclusion of this study was that, in study participants with hypothyroidism, there is a substantial link between “thyroid homeostasis and obesity”. In order to the best of our knowledge, only a few research have attempted to assess individuals with hypothyroidism utilising a sizable, “community-based sample” in order to discover a separate relationship between hypothyroidism and central obesity indices.

1. Introduction

A group of risk factors known as the “metabolic syndrome (MetS)”, which includes “hypertension, atherogenic dyslipidemia, hyperglycemia, truncal obesity, and even prothrombotic and proinflammatory diseases”, can increase the chance of developing “diabetes, cardiovascular disease, and death”. According to an International Diabetes Foundation survey, about a fifth of the

world's population has MetS (O'Neill et al, 2015) [1]. In clinical practise, it is common to see patients who have both “thyroid impairment and metabolic syndrome (MetS)”. In various population surveys, it has been estimated that more than 20% of adults meet the requirements for MetS (Palmer and Toth, 2019) [2]. A fluctuation in weight gain and adiposity is caused by the regulation of metabolic rate by THs and some of their metabolites. The central control of appetite and sympathetic activity

Journal of Coastal Life Medicine

is another area where THs have an impact. Adiposity has an adverse impact on thyroid function, and leptin has significant modulatory effects in this regard. Additionally, “pro-inflammatory cytokines” linked to IR and obesity may affect thyroid function and possibly its structure (Guan et al, 2017; McAninch EA and Bianco, 2014) [3,4].

Obesity, which is defined as a “BMI 30 kg/m²”, and abdominal obesity in particular, defined as a “waist circumference of >40 in (102 cm) for men or >35 in (88 cm) for women”, are linked to an elevated “risk of cardiovascular disease (CVD) and all-cause mortality” [5-7]. It frequently exhibits a number of metabolic problems, including “insulin resistance and atherogenic dyslipidemia” (“high levels of low-density lipoprotein particles and triglycerides [TG] and low levels of high-density lipoprotein cholesterol [HDL-C]”) [8,9]. “Atherosclerotic disease and acute cardiovascular events” are both more likely to occur in obese people due to their increased risk of “type 2 diabetes and metabolic syndrome” [10,11]. “Diabetes and insulin resistance” are linked to a wide range of pathophysiological outcomes, including a prooxidative state, an increased propensity to clot, endothelial dysfunction, and unfavourable cardiac remodelling [12,13].

When plasma free thyroxine (fT₄) concentrations are normal and serum thyrotropin (TSH) levels are elevated, this condition is known as subclinical hypothyroidism (SCH). - The prevalence of SCH varies between 4.6% and 16.7% in the population worldwide and is correlated with sex and age [14]. A probable link between SCH and obesity has been examined in earlier research [15, 16].

Hypothyroidism is the disorder arising from the absence of the influence of thyroid hormones on body tissues. It is a common disorder. The average occurrence in the population is around 1% to 2%. (Gayetal, 2000) [17] Serum TSH levels are greater than 10 mU/L and are associated with low thyroid hormone levels. It is possible to identify florid

hypothyroidism clinically.

2. Methods and Materials

The current investigation was carried out in the “General Medicine Outpatient Department at the Santosh Medical College and Hospital in Ghaziabad, Uttar Pradesh”. The study we conducted involved 100 patients. Weight and waist size were reported in a semi-structured manner. Blood pressure was gauged in the right upper limb while the subject was seated. Blood is taken in one sitting after an eight-hour fast in order to examine thyroid hormone levels, fasting blood sugar levels, and lipid profiles. Only individuals with abnormal TSH levels had their levels of fT₄ and fT₃ tested in order to screen the population for the frequency of thyroid diseases. With reference ranges of “3.1-6.8 pmol/L, 12-22 pmol/L, and 0.27-4.2 mIU/L, respectively, for -e fT₃, fT₄, and TSH”. Midstream urine samples were taken and kept cold overnight at 20°C. Using the ammonium persulfate technique, the “urinary iodine concentration (UIC)” was measured. An automated approach (BS180; Mindray, Ltd., Shenzhen, China) was used to quickly measure the levels of “fasting plasma glucose, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and serum total cholesterol (TC)”.

3. Results

The current study was carried out at the “Santosh Medical College and Hospital in Ghaziabad, Uttar Pradesh, in the Department of General Medicine” with the goal of determining the prevalence of hypothyroidism in patients with metabolic syndrome and evaluating the relationship between hypothyroidism and central obesity. The study involved a total of 100 patients. The distribution of thyroid dysfunction in our sample is shown in Table 1 and Fig. 1(a). Of the patients, “7% had hypothyroidism”. One in four individuals “(14%) had subclinical hypothyroidism”. Hypothyroidism was a “21% common condition” [Fig.1(b)].

Journal of Coastal Life Medicine

Table-1: Distribution of thyroids function and prevalence of hypothyroidism

Thyroid dysfunction	Frequency (%) (n=100)
Euthyroid	79(79%)
Hypothyroid	7(7%)
Subclinical hypothyroidism	14(14%)
Hypothyroidism	
Present	21(21%)
Absent	79(79%)




Figure 1(a): Distribution of thyroid dysfunction




Figure 1(b): Distribution of prevalence of hypothyroidism

Journal of Coastal Life Medicine

Table-2: Distribution of patients according to age & gender and its association with hypothyroidism

	Hypothyroidism		Normal		p-value
	No.	%	No.	%	
Age(yrs)					
30-40	5	16.7	25	83.3	0.63
41-50	9	20.5	35	79.5	
>50	7	26.9	19	73.1	
Gender					
Male	7	15.9	37	84.1	0.26
Female	14	25.0	42	75.0	

“In Table-2 & Fig.2 (a) shows the distribution of patients according to age and gender and its association with prevalence of hypothyroidism. More than one third of patients were between 41-50 years of age (44%) followed by 30-40(30%) and >50(26%) years and the prevalence of hypothyroidism was higher among patients of age >50 years (26.9%) than 41-50(20.5%) and 30-40(16.7%) years. However, there was no

significant ($p>0.05$) association of prevalence of hypothyroidism with age. Similarly, in Fig. 2(b) more than half of patients were females (56%) and the prevalence of hypothyroidism was higher among female patients (25%) than males (15.9%). However, there was no significant ($p>0.05$) association of prevalence of hypothyroidism with gender”.




Figure 2(a): Distribution of patients according to age and its association with hypothyroidism

Journal of Coastal Life Medicine




Figure 2(b): Distribution of patients according to gender and its association with hypothyroidism

Table-3: Comparison of anthropometric parameters with hypothyroidism

Anthropometric parameters	Hypothyroidism	Normal	p-value ¹
Height in cms	157.00±8.35	158.33±8.40	0.52
Weight in kgs	70.43±13.79	68.52±9.67	0.46
BMI in kg/mtr ²	28.52±4.67	27.32±3.27	0.17

¹Unpaired t-test

Table-3 shows the comparison of anthropometric parameters between with and without hypothyroidism. There was no significant ($p > 0.05$)

difference in anthropometric parameters between with and without hypothyroidism.

Table-4: Distribution of patients according to central obesity and its association with hypothyroidism

Central obesity	No.(n=100)		Hypothyroidism		Normal		p-value ¹
	No.	%	No.	%	No.	%	
Lowrisk	41	41.0	3	7.3	38	92.7	0.007
Highrisk	51	51.0	14	27.5	37	72.5	
Increasedhighrisk	8	8.0	4	50.0	4	50.0	

Table-4 & Fig.3 shows the distribution of patients according to central obesity and its association with prevalence of hypothyroidism. “High risk of central obesity was among about half of patients (51) and the prevalence of hypothyroidism was

higher among increased high risk central obesity (50%) than high risk (27.5%) and low risk (7.3%)”. There was significant (“ $p = 0.007$ ”) “association of prevalence of hypothyroidism with central obesity”.




Figure 3: “Distribution of patients according to central obesity and its association with hypothyroidism”

Table-4: Comparison of mean blood pressure with hypothyroidism

Blood pressure	Hypothyroidism	Normal	p-value ¹
SBP	142.67±13.33	138.51±13.99	0.22
DBP	88.73±6.97	87.81±7.87	0.60

Table- 4 & Fig.4 shows the comparison of blood pressure with hypothyroidism. There was no

significant ($p > 0.05$) difference in blood pressure between hypothyroidism patients than normal.




Figure 4: Comparison of mean blood pressure with hypothyroidism

4. Discussion

“This study showed that more than one third of patients were between 41-50 years of age (44%) followed by 30-40 (30%) and >50 (26%) years. In

this study, the prevalence of hypothyroidism was higher among patients of age >50 years (26.9%) than 41-50 (20.5%) and 30-40 (16.7%) years”. However, there was no significant ($p > 0.05$) association of prevalence of hypothyroidism with

Journal of Coastal Life Medicine

age. Deshmukh et al (2018) [18] In the higher age group (<45 years of age), both men and women had a higher prevalence of thyroid dysfunction (men: 63 percent's. 37 percent; women: 59 percent vs. 41 percent). The outcome of the latest research that we have carried out states that there was a tendency of increase in TD with ageing for both sexes, in accordance with other studies. (Meng et al, 2015; Tehrani et al, 2011) [20,21]. Aljabri et al (2019) [19] reported that the prevalence of hypothyroidism was non-significantly greater across all age groups but significantly higher in all decades ($p=0.0001$). Females younger than 60 years of age had a non-significantly higher prevalence of hypothyroidism.

5. Conclusion

In conclusion, results from a community-based and representative cohort showed that SPINA-GT and TSHI were negatively linked with BMI in persons with "SCH regardless of age, sex, smoking, iodine status, and glucolipid metabolism".

The prevalence of "hypothyroidism" was higher among patients with increased high risk central obesity (50%) than among those with "high risk (27.5%) and low risk (7.3%)", which accounted for almost half of patients (51%) with high risk of central obesity. The prevalence of hypothyroidism and central obesity were significantly correlated ($p=0.007$). Of the patients, 42% had hypertension.

Further study is necessary to determine whether intensive treatment, such as ongoing thyroid homeostasis testing or thyroid hormone replacement therapy for those with SCH, can enhance metabolism and adiposity status.

Limitation: Several restrictions applied to this investigation. First, the study's cross-sectional design leaves unclear whether obesity in patients with SCH is a result of significantly low thyroid homeostasis indices or whether obesity is the source of such low levels.

References:

1. O'Neill S., O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. *Obesity Reviews*. 2015;16(1):1-12.
2. Palmer MK and Toth PP. Trends in lipids, obesity, metabolic syndrome, and diabetes mellitus in the United States: an NHANES analysis (2003-2004 to 2013-2014). *Obesity* 2019; 27: 309-314.
3. Guan B, Chen YY, Yang W, et al. Effect of bariatric surgery on thyroid function in obese patients: a systematic review and meta-analysis. *Obes Surg* 2017; 27: 3292-3305.
4. McAninch EA and Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. *Ann N Y Acad Sci* 2014; 1311: 77-8.
5. Jiang J, Ahn J, Huang WY, Hayes RB. Association of obesity with cardiovascular disease mortality in the PLCO trial. *Prev Med* 2013;57:60-64.
6. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med* 2010;363:2211-2219.
7. Czernichow S, Kengne AP, Huxley RR, et al. Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. *Eur J Cardiovasc Prev Rehabil* 2011;18:312-319.
8. Singh M, Arora R, Kodumuri V, Khosla S, Jawad E. Coronary revascularization in diabetic patients: current state of evidence. *Exp Clin Cardiol* 2011;16:16-22.
9. Kaur J. A comprehensive review on metabolic syndrome. *Cardiol Res Pract* 2014;2014:943162. doi:10.1155/2014/943162
10. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143-3421.
11. Garca-Estevez DA, Araújo-Vilar D, Saavedra-González A, Fiestras-Janeiro G, Cabezas-Cerrato J. Analysis of the relationship between body mass index, insulin resistance, and beta-cell function: a cross-sectional study using the minimal model. *Metabolism* 2004;53:1462-1466.

Journal of Coastal Life Medicine

12. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. *World J Diabetes* 2015;6:1246-1258.
13. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. *Int J Hypertens* 2013;2013:653789. doi:10.1155/2013/653789
14. P. N. Taylor, D. Albrecht, A. Scholz et al., "Global epidemiology of hyperthyroidism and hypothyroidism," *Nature Reviews Endocrinology*, vol. 14, no. 5, pp. 301–316, 2018.
15. L. T. van Hulsteijn, R. Pasquali, F. Casanueva et al., "Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis," *European Journal of Endocrinology*, vol. 182, no. 1, pp. 11–21, 2020.
16. M.-K. Lee, Y. M. Kim, S.-Y. Sohn, J.-H. Lee, Y. J. Won, and S. H. Kim, "Evaluation of the relationship of subclinical hypothyroidism with metabolic syndrome and its components in adolescents: a population-based study," *Endocrine*, vol. 65, no. 3, pp. 608–615, 2019.
17. Gay JC et al. The Colorado thyroid disease prevalence study. *Arch intern med* 2000;160:526-534
18. Deshmukh V, Farishta F, Bhole M. Thyroid Dysfunction in Patients with Metabolic Syndrome: A Cross-Sectional, Epidemiological, Pan-India Study. *Int J Endocrinol*.2018.
19. Aljabri KS, Alnasser IM, Bokhari SA, Alshareef MA, Khan PM, et al. The Prevalence of Hypothyroidism in Patients with Metabolic Syndrome in Saudi Community Based Hospital: A Retrospective Single Centre Study. *Int J Diabetes Clin Res* 2019;6(103).
20. Meng Z., Liu M., Zhang Q. et al. Gender and age impacts on the association between thyroid function and metabolic syndrome in Chinese. *Medicine* 2015;94(50).
21. Tehrani F. R., Tohidi M., and Dovom M. R. A population based study on the association of thyroid status with components of the metabolic syndrome. *Journal of Diabetes & Metabolism* 2011;2(8)